World Drug Report 2011

Many illicit drug markets have reached global dimensions and require control strategies on a comparable scale. In that context, there is a need to better understand these transnational markets and the manner in which they operate. The annual Report, produced by the United Nations Office on Drugs and Crime, is a contribution towards that objective. It provides an overview of the illicit drug situation worldwide and regionally, analytical discussions of the key transnational drug markets and statistical trends for all major drug categories.

The 2019 World Drug Report will include an updated overview of recent trends on production, trafficking and consumption of key illicit drugs. The Report contains a global overview of the baseline data and estimates on drug demand and supply and provides the reference point for information on the drug situation worldwide.

As in previous reports, the 2021 World Drug Report (WDR) aims to improve the understanding of the world’s drug problem and to contribute towards fostering greater international cooperation for countering its impact on health, governance and security. Also, to the extent possible, the WDR contributes to the monitoring and reporting of SDGs. This edition includes an updated overview of recent trends on production, trafficking and consumption for non-medical purposes of key controlled substances. It further maintains a global overview of the baseline data and estimates on drug demand and supply and provides an analysis of the market for the different drugs.

The 2017 WDR will include an updated overview of recent trends on production, trafficking and consumption of key illicit drugs as well as highlighting a thematic area of concern. The Report will maintain a global overview of the baseline data and estimates on drug demand and supply. This part will be descriptive and less analytical to fulfill one of the main functions of the report which is to provide the reference point of information on the drug situation worldwide. Other parts will be more analytical and will look in depth at few specific topics. Issues which will be highlighted in analysing new trends were selected on the basis of available research findings discussed within RAB and other internal and external stakeholders, including the members of the WDR Scientific Advisory Committee (SAC). The thematic focus of the 2017 Report will be on the links between drugs, terrorism, corruption, transnational organized crime and illicit financial flows.

Drawing on the Household Living Arrangements of Older Persons 2019 Dataset, the World Population Ageing 2020 Highlights will document key patterns and trends of the household living arrangements of older persons around the world.

Advances in medical, biomedical and health services research have reduced the level of uncertainty in clinical practice. Clinical practice guidelines (CPGs) complement this progress by establishing standards of care backed by strong scientific evidence. CPGs are statements that include recommendations intended to optimize patient care. These statements are informed by a systematic review of evidence and an assessment of the benefits and costs of alternative care options. Clinical Practice Guidelines We Can Trust examines the current state of clinical practice guidelines and how they can be improved to enhance healthcare quality and patient outcomes. Clinical practice guidelines now are ubiquitous in our healthcare system. The Guidelines International Network (GIN) database currently lists more than 3,700 guidelines from 39 countries. Developing guidelines presents a number of challenges including lack of transparent methodological practices, difficulty reconciling conflicting guidelines, and conflicts of interest. Clinical Practice Guidelines We Can Trust explores questions surrounding the quality of CPG development processes and the establishment of standards. It proposes eight standards for developing trustworthy clinical practice guidelines emphasizing transparency; management of conflict of interest ; systematic review-guideline development intersection; establishing evidence foundations for and rating strength of guideline recommendations; articulation of recommendations; external review; and updating. Clinical Practice Guidelines We Can Trust shows how clinical practice guidelines can enhance clinician and patient decision-making by translating complex scientific research findings into recommendations for clinical practice that are relevant to the individual patient encounter, instead of implementing a one size fits all approach to patient care. This book contains information directly related to the work of the Agency for Healthcare Research and Quality (AHRQ), as well as various Congressional staff and policymakers. It is a vital resource for medical specialty societies, disease advocacy groups, health professionals, private and international organizations that develop or use clinical practice guidelines, consumers, clinicians, and payers.

The World Drug Report provides an annual overview of recent developments for various drug categories. Chapter one of the World Drug Report 2015 provides a global overview of the latest developments with respect to opiates, cocaine, cannabis and synthetic drugs, ranging from production to trafficking as well as consumption and the health impact of drug use. Chapter two focuses on Alternative Development, its relation to illicit cultivation, and also within the broader context of the development agenda.

Estimates indicate that as many as 1 in 4 Americans will experience a mental health problem or will misuse alcohol or drugs in their lifetimes. These disorders are among the most highly stigmatized health conditions in the United States, and they remain barriers to full participation in society in areas as basic as education, housing, and employment. Improving the lives of people with mental health and substance abuse disorders has been a priority in the United States for more than 50 years. The Community Mental Health Act of 1963 is considered a major turning point in America's efforts to improve behavioral healthcare. It ushered in an era of optimism and hope and laid the groundwork for the consumer movement and new models of recovery. The consumer movement gave voice to people with mental and substance use disorders and brought their perspectives and experience into national discussions about mental health. However over the same 50-year period, positive change in American public attitudes and beliefs about mental and substance use disorders has lagged behind these advances. Stigma is a complex social phenomenon based on a relationship between an attribute and a stereotype that assigns undesirable labels, qualities, and behaviors to a person with that attribute. Labeled individuals are then socially devalued, which leads to inequality and discrimination. This report contributes to national efforts to understand and change attitudes, beliefs and behaviors that can lead to stigma and discrimination. Changing stigma in a lasting way will require coordinated efforts, which are based on the best possible evidence, supported at the national level with multiyear funding, and planned and implemented by an effective coalition of representative stakeholders. Ending Discrimination Against People with Mental and Substance Use Disorders: The Evidence for Stigma Change explores stigma and discrimination faced by individuals with mental or substance use disorders and recommends effective strategies for reducing stigma and encouraging people to seek treatment and other supportive services. It offers a set of conclusions and recommendations about successful stigma change strategies and the research needed to inform and evaluate these efforts in the United States.